NAD+ (Nicotinamide Adenine Dinucleotide) Evidence Grade: A-
NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme found in every living cell, serving as a critical cofactor for over 500 enzymatic reactions and as a substrate for signaling enzymes including sirtuins and PARPs. It is indispensable for cellular energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), DNA repair, gene expression regulation, calcium signaling, and maintenance of cellular redox balance.
NAD+ levels decline significantly with age, decreasing by approximately 40-50% between ages 40 and 60. This decline is now recognized as a hallmark of aging that contributes to mitochondrial dysfunction, impaired DNA repair, metabolic deterioration, and increased susceptibility to age-related diseases. Restoring NAD+ levels through direct supplementation (IV, SubQ) or precursor molecules (NMN, NR) has become a major focus of longevity research and clinical practice.
Table of Contents
Overview & Introduction
NAD+ exists in two forms: the oxidized form (NAD+) and the reduced form (NADH). Together they constitute the NAD+/NADH redox pair that shuttles electrons in metabolic reactions. Beyond its role as an electron carrier, NAD+ serves as a consumable substrate for three critical enzyme families: sirtuins (SIRT1-7, gene regulation and aging), PARPs (poly-ADP-ribose polymerases, DNA repair), and CD38/CD157 (calcium signaling and immune function). These enzymes cleave NAD+ to perform their functions, meaning NAD+ is continuously consumed and must be regenerated.
The age-related decline in NAD+ is driven by multiple factors: increased consumption by PARPs responding to accumulating DNA damage; rising CD38 activity associated with chronic low-grade inflammation (inflammaging); decreased expression of NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway; and increased oxidative stress. This decline creates a vicious cycle where reduced NAD+ impairs the very repair and maintenance pathways that would otherwise prevent further decline.
The discovery by David Sinclair, Leonard Guarente, and others that NAD+ decline is a unifying mechanism linking multiple hallmarks of aging has positioned NAD+ restoration as a central strategy in longevity research. Studies in aged mice have shown that NAD+ repletion (via NMN or NR supplementation) can reverse age-related mitochondrial dysfunction, improve metabolic function, enhance DNA repair capacity, and extend healthy lifespan.
NAD+ can be administered directly via intravenous infusion or subcutaneous injection, or indirectly through oral precursors including NMN (nicotinamide mononucleotide), NR (nicotinamide riboside), and niacin (nicotinic acid). Each approach has distinct pharmacokinetic properties, tissue distribution patterns, and practical considerations. IV NAD+ therapy has become popular in clinical practice despite limited controlled trial data, while precursor supplementation has more clinical trial support for oral bioavailability and tissue NAD+ elevation.
History & Discovery
Discovery. Arthur Harden and William John Young discovered NAD+ as a cell-free fermentation factor, originally calling it "cozymase." This work contributed to Harden's 1929 Nobel Prize in Chemistry.
Structure elucidation. Hans von Euler-Chelpin determined the chemical structure of NAD+ as a dinucleotide, establishing its role as a hydrogen carrier in metabolic reactions.
Sirtuin-NAD+ connection. Leonard Guarente's lab demonstrated that the yeast longevity gene Sir2 is an NAD+-dependent deacetylase, linking NAD+ to lifespan regulation for the first time.
Aging reversal in mice. David Sinclair's group published landmark studies showing that NAD+ repletion via NMN reversed age-related mitochondrial dysfunction in aged mice, making them metabolically indistinguishable from young mice.
Human clinical trials. Multiple clinical trials of NMN, NR, and direct NAD+ supplementation in humans were initiated. IV NAD+ therapy became widely available in clinical practice. Research continues to define optimal dosing, delivery routes, and clinical endpoints.
Mechanism of Action
NAD+ is the essential substrate for all seven mammalian sirtuins. SIRT1 deacetylates PGC-1alpha (mitochondrial biogenesis), p53 (apoptosis regulation), FOXO transcription factors (stress resistance), and NF-kB (inflammation). SIRT3 regulates mitochondrial metabolism. SIRT6 maintains telomere integrity and DNA repair. When NAD+ levels decline, sirtuin activity drops, leading to mitochondrial dysfunction, increased inflammation, and impaired stress responses.
PARP1 and PARP2 are DNA damage sensors that consume NAD+ to synthesize poly-ADP-ribose chains at DNA break sites, recruiting repair machinery. As DNA damage accumulates with age, PARP activity increases, consuming more NAD+. This creates competition between PARPs and sirtuins for the declining NAD+ pool, forcing a trade-off between DNA repair and gene regulation. NAD+ repletion alleviates this competition, allowing both functions to operate optimally.
NAD+/NADH cycling is central to ATP production. In glycolysis, NAD+ accepts electrons to become NADH. In the mitochondria, NADH donates electrons to Complex I of the electron transport chain, regenerating NAD+ and driving ATP synthesis. NAD+ decline reduces mitochondrial membrane potential, ATP output, and overall cellular energy capacity, contributing to the fatigue and metabolic decline of aging.
CD38 is a NAD+-consuming ectoenzyme expressed on immune cells whose activity increases with aging and chronic inflammation. CD38 is now recognized as the primary NAD+-consuming enzyme in aged tissues, responsible for the majority of age-related NAD+ decline. Targeting CD38 (with inhibitors like apigenin) alongside NAD+ supplementation may be synergistic for NAD+ restoration.
Research Applications
Aging & Longevity
NAD+ restoration is a cornerstone of longevity research. Animal studies demonstrate reversal of age-related metabolic decline, improved mitochondrial function, enhanced DNA repair, and extended healthy lifespan with NAD+ repletion.
Neurodegenerative Disease
NAD+ decline contributes to neuronal energy failure in Alzheimer's, Parkinson's, and ALS. NAD+ repletion protects neurons from excitotoxicity, improves mitochondrial function in neural tissue, and enhances axonal regeneration.
Metabolic Disease
NAD+ modulates insulin sensitivity, lipid metabolism, and glucose homeostasis through sirtuin-mediated pathways. Research explores NAD+ supplementation for type 2 diabetes, obesity, and non-alcoholic fatty liver disease.
Cardiovascular Health
NAD+ supports cardiac muscle energetics, vascular endothelial function, and protection against ischemia-reperfusion injury. Preclinical evidence suggests cardioprotective effects of NAD+ restoration.
Addiction & Mental Health
IV NAD+ therapy has been used in addiction recovery protocols, with observational reports of reduced withdrawal symptoms and cravings. Controlled clinical evidence for this application is still developing.
Clinical Evidence
Age-Related NAD+ Decline and Reversal in Mice
Gomes et al. (2013) demonstrated that NAD+ levels decline with age in mouse tissues and that one week of NMN treatment reversed age-related mitochondrial dysfunction. Treated old mice showed mitochondrial parameters indistinguishable from young mice. This landmark study established the therapeutic potential of NAD+ repletion for aging.
PMID: 24360282
NMN Safety and Efficacy in Humans
Yoshino et al. (2021) conducted a randomized, placebo-controlled, double-blind trial of NMN (250 mg/day) in postmenopausal women with prediabetes. NMN supplementation significantly increased muscle insulin sensitivity, improved insulin signaling, and increased muscle NAD+ metabolite levels. This was one of the first rigorous clinical demonstrations of NMN's metabolic benefits in humans.
PMID: 33888596
NR Raises NAD+ in Humans
Martens et al. (2018) conducted a crossover clinical trial of nicotinamide riboside (NR, 500 mg twice daily) in healthy middle-aged and older adults. NR supplementation increased whole blood NAD+ levels by approximately 60%, reduced systolic blood pressure, and reduced aortic stiffness. The study provided the first evidence that oral NAD+ precursor supplementation can raise NAD+ levels and improve cardiovascular parameters in humans.
PMID: 29599478
CD38 as Major NAD+ Consumer
Camacho-Pereira et al. (2016) identified CD38 as the primary enzyme responsible for age-related NAD+ decline. CD38 knockout mice maintained youthful NAD+ levels into old age. The study demonstrated that CD38 activity increases with chronic inflammation, providing a mechanistic target for NAD+ preservation strategies.
PMID: 27304511
Dosing Protocols (Research Context)
Note: NAD+ and its precursors are not FDA-approved drugs. Dosing information reflects published research and clinical practice protocols.
| Route | Dose | Frequency |
|---|---|---|
| IV NAD+ Infusion | 250-750 mg (over 2-4 hours) | 1-2 times weekly or monthly |
| SubQ NAD+ Injection | 50-200 mg | Daily or 3x weekly |
| Oral NMN | 250-1000 mg/day | Daily, long-term |
| Oral NR | 300-1000 mg/day | Daily, long-term |
IV infusion provides direct systemic NAD+ elevation but requires clinical setting and 2-4 hour infusion time. SubQ injection is a more practical alternative for regular administration. Oral precursors are the most convenient for long-term daily use and have the most clinical trial support.
Administration & Reconstitution
IV Infusion
NAD+ is diluted in sterile saline (250-500 mL) and infused slowly over 2-4 hours. Rapid infusion can cause flushing, chest tightness, nausea, and cramping. Medical supervision required.
SubQ Injection
NAD+ solution (typically 100 mg/mL) injected subcutaneously using insulin syringes. May cause local burning or stinging at injection site. Rotate injection locations.
Oral Precursors
NMN and NR are available as capsules/powder. No reconstitution needed. Take with or without food (absorption may be enhanced in fasted state for some formulations).
Side Effects & Safety Profile
NAD+ is an endogenous molecule with a favorable safety profile. Side effects are primarily associated with the route of administration rather than the compound itself.
IV Infusion Side Effects
- Nausea during infusion (rate-dependent)
- Flushing and warmth
- Chest or abdominal tightness
- Muscle cramping
- Headache
SubQ/Oral Side Effects
- Injection site burning/stinging (SubQ)
- Mild GI discomfort (oral precursors)
- Flushing (niacin pathway; less with NMN/NR)
- Generally well-tolerated
Most IV side effects resolve by slowing infusion rate. No serious adverse events have been reported in clinical trials of NMN or NR at standard doses. Long-term safety data (5+ years) is still accumulating.
Stacking & Combinations
NAD+ + Resveratrol/Pterostilbene
Sirtuin activators (resveratrol, pterostilbene) require NAD+ as substrate. Combining NAD+ precursors with sirtuin activators may produce synergistic effects on sirtuin-dependent pathways. Sinclair's research group has championed this combination.
NAD+ + Epithalon
For comprehensive anti-aging: NAD+ restores cellular energy metabolism and DNA repair capacity while Epithalon activates telomerase and restores pineal function. Addresses aging from both metabolic and chromosomal perspectives.
NAD+ + GHK-Cu
NAD+ provides the cellular energy and repair capacity while GHK-Cu resets gene expression toward youthful patterns. Together they address both cellular energy decline and gene expression aging.
NAD+ + CD38 Inhibitors
Apigenin, quercetin, and other CD38 inhibitors can reduce NAD+ consumption, complementing supplementation strategies. This "supply and demand" approach may be more effective than supplementation alone.
Storage & Stability
| Form | Conditions | Duration |
|---|---|---|
| NAD+ Lyophilized | Frozen (-20°C) | 24+ months |
| NAD+ Solution (injection) | Refrigerated | 28 days |
| NMN Capsules/Powder | Cool, dry, dark | Per manufacturer |
| NR Capsules | Cool, dry | Per manufacturer |
- NAD+ is hygroscopic; protect from moisture
- NAD+ solutions degrade faster than lyophilized form
- Protect from light and heat
Regulatory Status
- United States: NAD+ is not FDA-approved as a drug. Available through compounding pharmacies and IV clinics. NMN was briefly classified as a drug candidate (preventing supplement sale) but regulatory status continues to evolve. NR is sold as a dietary supplement (Tru Niagen).
- EU: NR available as a novel food ingredient. NAD+ IV therapy varies by member state.
- WADA: NAD+ and precursors are not prohibited.
Frequently Asked Questions
What is the difference between NAD+, NMN, and NR?
Why do NAD+ levels decline with age?
Is NAD+ IV therapy supported by clinical evidence?
References
- Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624-1638. PMID: 24360282
- Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224-1229. PMID: 33888596
- Martens CR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nat Commun. 2018;9(1):1286. PMID: 29599478
- Camacho-Pereira J, et al. "CD38 dictates age-related NAD decline." Cell Metab. 2016;23(6):1127-1139. PMID: 27304511
Related Pages
Concise compound overview
Step-by-step protocol
Anti-aging partner
Gene modulation partner
Track NAD+ markers
Medical Disclaimer: This article is for educational and research purposes only. NAD+ and its precursors are not FDA-approved treatments for any disease. Consult a healthcare professional. See our full Medical Disclaimer.
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.